RedHill Biopharma Terminates License Agreement for Aemcolo®

Core Viewpoint - RedHill Biopharma Ltd. has mutually decided with Cosmo Technologies Ltd. to terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea, effective October 8, 2024 [3][6][11]. Company Overview - RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, promoting drugs such as Talicia® for H. pylori infection and Aemcolo® for traveler's diarrhea [11]. - The company is engaged in late-stage development programs including opaganib for multiple indications and RHB-107 for symptomatic COVID-19, with external funding covering the RHB-107 arm of a Phase 2 trial [11]. License Agreement Details - The License Agreement for Aemcolo was initially dated October 17, 2019, and will officially terminate on October 8, 2024, after which all rights will revert to Cosmo [3][6]. - RedHill will cease any commercialization efforts for Aemcolo immediately upon termination of the License Agreement [6]. Future Development Plans - RedHill's key clinical programs include: - Opaganib, a first-in-class oral SPHK2 selective inhibitor, targeting indications such as Acute Radiation Syndrome and COVID-19 [11]. - RHB-107, an oral serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 [11]. - Other programs targeting gastrointestinal diseases and oncology [11].